About Ocera Therapeutics (NASDAQ:OCRX)
Ocera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger. It is conducting a randomized, placebo-controlled double blind Phase IIb clinical trial to evaluate the efficacy of intravenous administration of OCR-002 IV formulation in reducing the severity of HE symptoms among HE patients. The Company also conducted a Phase IIa investigator-sponsored trial of OCR-002 in Spain in patients with upper gastrointestinal bleeding associated with liver cirrhosis. It is developing an oral form of OCR-002 to provide continuity of care for HE patients, where the intravenous form is used for hospital-based acute care and the oral form for chronic maintenance care post discharge.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / Sales77.79
Price / CashN/A
Book Value$0.68 per share
Price / Book2.63
EPS (Most Recent Fiscal Year)N/A
Return on Equity-383.51%
Return on Assets-134.92%
Ocera Therapeutics (NASDAQ:OCRX) Frequently Asked Questions
What is Ocera Therapeutics' stock symbol?
Ocera Therapeutics trades on the NASDAQ under the ticker symbol "OCRX."
How were Ocera Therapeutics' earnings last quarter?
Ocera Therapeutics Inc (NASDAQ:OCRX) posted its quarterly earnings results on Tuesday, November, 14th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.24). View Ocera Therapeutics' Earnings History.
What price target have analysts set for OCRX?
3 equities research analysts have issued 1 year target prices for Ocera Therapeutics' shares. Their forecasts range from $1.75 to $11.00. On average, they expect Ocera Therapeutics' stock price to reach $5.25 in the next twelve months. View Analyst Ratings for Ocera Therapeutics.
Who are some of Ocera Therapeutics' key competitors?
Some companies that are related to Ocera Therapeutics include Aviat Networks (AVNW), A-Mark Precious Metals (AMRK), Galmed Pharmaceuticals (GLMD), Luna Innovations (LUNA), MaxPoint Interactive (MXPT), Anavex Life Sciences (AVXL), TheStreet (TST), Medgenics (GNMX), DavidsTea (DTEA), American River Bank (AMRB), BioLineRx (BLRX), S&w Seed (SANW), Aptevo Therapeutics (APVO), Travelzoo (TZOO), Lifeway Foods (LWAY), Stein Mart (SMRT), Invuity (IVTY) and Alphatec (ATEC).
Who are Ocera Therapeutics' key executives?
Ocera Therapeutics' management team includes the folowing people:
- Linda S. Grais M.D., President, Chief Executive Officer, Director (Age 61)
- Michael Byrnes, Principal Financial Officer, Chief Accounting Officer, Vice President - Finance, Treasurer (Age 38)
- Stan Bukofzer M.D., Chief Medical Officer (Age 59)
- Steven P. James, Lead Independent Director (Age 57)
- Willard H. Dere M.D., Director (Age 63)
- Nina S. Kjellson, Independent Director (Age 40)
- Anne M. VanLent, Independent Director (Age 68)
- Eckard Weber M.D., Independent Director (Age 66)
Has Ocera Therapeutics been receiving favorable news coverage?
News articles about OCRX stock have trended somewhat positive this week, Accern Sentiment reports. The research firm scores the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Ocera Therapeutics earned a news impact score of 0.12 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 47.74 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
How do I buy shares of Ocera Therapeutics?
Shares of OCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ocera Therapeutics' stock price today?
One share of OCRX stock can currently be purchased for approximately $1.79.
How big of a company is Ocera Therapeutics?
Ocera Therapeutics has a market capitalization of $47.46 million and generates $610,000.00 in revenue each year. Ocera Therapeutics employs 19 workers across the globe.
How can I contact Ocera Therapeutics?
Ocera Therapeutics' mailing address is 555 Twin Dolphin Dr Ste 615, REDWOOD CITY, CA 94065-2130, United States. The biopharmaceutical company can be reached via phone at +1-650-4750158 or via email at [email protected]
MarketBeat Community Rating for Ocera Therapeutics (OCRX)MarketBeat's community ratings are surveys of what our community members think about Ocera Therapeutics and other stocks. Vote "Outperform" if you believe OCRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OCRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Ocera Therapeutics (NASDAQ:OCRX) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Ocera Therapeutics (NASDAQ OCRX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 7.24%
Institutional Ownership Percentage: 17.69%
Ocera Therapeutics (NASDAQ OCRX) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|3/28/2017||Michael Byrnes||CFO||Buy||3,000||$1.28||$3,840.00||13,000|| |
|12/7/2016||Linda S Grais||Insider||Buy||7,000||$2.14||$14,980.00||70,000|| |
|10/13/2016||Stan Bukofzer||Insider||Buy||2,500||$2.64||$6,600.00||2,500|| |
|3/4/2016||Linda S Grais||CEO||Buy||3,000||$3.19||$9,570.00||63,000|| |
|1/22/2016||Linda S Grais||CEO||Buy||10,000||$2.38||$23,800.00||60,000|| |
|1/15/2016||Gaurav Aggarwal||Insider||Buy||10,000||$2.15||$21,500.00||20,000|| |
|1/15/2016||Michael Byrnes||CFO||Buy||3,500||$2.07||$7,245.00||10,000|| |
|6/23/2015||Wendall Wierenga||Director||Buy||5,000||$3.71||$18,550.00|| |
|5/7/2015||Rajiv Patni||Insider||Buy||5,050||$3.97||$20,048.50|| |
|5/6/2015||Gaurav Aggarwal||Insider||Buy||7,500||$3.62||$27,150.00|| |
|5/6/2015||Linda S Grais||CEO||Buy||30,000||$3.73||$111,900.00|| |
|5/6/2015||Michael Byrnes||CFO||Buy||2,500||$3.61||$9,025.00|| |
|10/1/2014||Michael Byrnes||VP||Buy||2,000||$4.81||$9,620.00|| |
|7/11/2014||Linda S Grais||CEO||Buy||10,000||$5.93||$59,300.00|| |
|7/11/2014||Sharon Tetlow||CFO||Buy||3,000||$5.83||$17,490.00|| |
|7/15/2013||Brian K Halak||Major Shareholder||Buy||995,618||$6.03||$6,003,576.54|| |
|7/15/2013||Michael Powell||Director||Buy||391,166||$6.03||$2,358,730.98|| |
Ocera Therapeutics (NASDAQ OCRX) News Headlines
|Zacks Investment Research Upgrades Ocera Therapeutics (OCRX) to Hold|
www.americanbankingnews.com - April 14 at 12:53 PM
|Ocera Therapeutics (OCRX) Upgraded by Zacks Investment Research to Buy|
www.americanbankingnews.com - April 12 at 9:35 PM
|Ocera Therapeutics (OCRX) Rating Lowered to Sell at Zacks Investment Research|
www.americanbankingnews.com - April 1 at 11:52 AM
|Head to Head Analysis: Ocera Therapeutics (OCRX) and Vitae Pharmaceuticals (VTAE)|
www.americanbankingnews.com - March 26 at 5:36 PM
|VIVUS (VVUS) and Ocera Therapeutics (OCRX) Financial Analysis|
www.americanbankingnews.com - March 6 at 1:18 AM
|Sinovac Biotech (SVA) & Ocera Therapeutics (OCRX) Financial Survey|
www.americanbankingnews.com - February 6 at 9:14 AM
|Contrasting Ocera Therapeutics (OCRX) and 3SBio (SSRX)|
www.americanbankingnews.com - February 2 at 3:38 PM
|Ocera Therapeutics (OCRX) & Synlogic (SYBX) Financial Contrast|
www.americanbankingnews.com - January 27 at 5:20 AM
|Analyzing Auxilium Pharmaceuticals (AUXL) & Ocera Therapeutics (OCRX)|
www.americanbankingnews.com - January 22 at 5:20 AM
|Ocera Therapeutics Inc (OCRX) Receives Consensus Recommendation of "Hold" from Brokerages|
www.americanbankingnews.com - January 12 at 8:36 PM
|Ocera Therapeutics Inc (OCRX) Given Consensus Recommendation of "Hold" by Analysts|
www.americanbankingnews.com - December 18 at 10:16 PM
|Ocera Therapeutics (OCRX) Given "Buy" Rating at Cowen|
www.americanbankingnews.com - December 18 at 8:26 PM
|Want To Invest In Ocera Therapeutics Inc (undefined:OCRX)? Here’s How It Performed Lately|
finance.yahoo.com - December 13 at 8:29 AM
|SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Files Class Action Suit Against Ocera Therapeutics, Inc.|
feeds.benzinga.com - December 7 at 9:47 PM
| Brokerages Expect Ocera Therapeutics, Inc. (OCRX) Will Post Earnings of -$0.20 Per Share|
www.americanbankingnews.com - December 6 at 7:52 AM
| Analysts Anticipate Ocera Therapeutics, Inc. (OCRX) to Announce -$0.20 Earnings Per Share|
www.americanbankingnews.com - November 18 at 1:30 PM
|At $1.75, Is It Time To Buy Ocera Therapeutics Inc (OCRX)?|
finance.yahoo.com - November 18 at 10:08 AM
|Ocera Therapeutics, Inc. (OCRX) Stock Rating Lowered by HC Wainwright|
www.americanbankingnews.com - November 5 at 6:20 PM
|SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Ocera Therapeutics, Inc. to Mallinckrodt plc is Fair to Shareholders|
finance.yahoo.com - November 4 at 4:07 PM
|OCERA THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout|
finance.yahoo.com - November 4 at 4:07 PM
|Mid-Afternoon Market Update: Ocera Therapeutics Surges Following ... - Nasdaq|
www.nasdaq.com - November 4 at 8:23 AM
|SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Ocera Therapeutics, Inc. - OCRX - PR Newswire (press release)|
www.prnewswire.com - November 4 at 8:23 AM
|Mallinckrodt to Acquire Ocera Therapeutics and OCR-002, its Proprietary Therapy in Development for Treatment of Hepatic Encephalopathy|
finance.yahoo.com - November 2 at 7:13 AM
|Mallinckrodt will buy biotech Ocera Therapeutics for about $42 mln|
finance.yahoo.com - November 2 at 7:13 AM
|Ocera Therapeutics, Inc. (OCRX) Sees Large Decline in Short Interest|
www.americanbankingnews.com - October 28 at 2:26 AM
|Contrasting KalVista Pharmaceuticals (KALV) and Ocera Therapeutics (OCRX)|
www.americanbankingnews.com - October 27 at 7:24 PM
|Ocera Therapeutics (OCRX) to Present Three Posters, Oral Presentation on OCR-002 at AASLD - StreetInsider.com|
www.streetinsider.com - October 21 at 7:18 AM
|Ocera Presents Three Posters and an Oral Presentation on OCR-002 at the AASLD Liver Meeting®|
finance.yahoo.com - October 21 at 7:18 AM
|Ocera Therapeutics, Inc. (OCRX) Given Average Rating of "Buy" by Brokerages|
www.americanbankingnews.com - October 19 at 1:24 PM
|Critical Review: Chiasma (CHMA) & Ocera Therapeutics (OCRX)|
www.americanbankingnews.com - October 6 at 2:08 AM
|Will Ocera Therapeutics Inc (OCRX) Need To Raise More Money?|
finance.yahoo.com - October 5 at 6:37 PM
|Ocera Therapeutics, Inc. (OCRX) Receives Average Rating of "Buy" from Brokerages|
www.americanbankingnews.com - September 24 at 10:36 AM
|Ocera Therapeutics, Inc. (OCRX) Expected to Announce Earnings of -$0.23 Per Share|
www.americanbankingnews.com - September 21 at 6:24 AM
|Reviewing Baxalta (BXLT) & Ocera Therapeutics (OCRX)|
www.americanbankingnews.com - September 20 at 12:16 AM
|Financial Contrast: Catalyst Biosciences (CBIO) vs. Ocera Therapeutics (OCRX)|
www.americanbankingnews.com - September 16 at 6:30 PM
|Head-To-Head Survey: Ocera Therapeutics (OCRX) & Its Peers|
www.americanbankingnews.com - September 13 at 6:20 AM
| Analysts Anticipate Ocera Therapeutics, Inc. (OCRX) Will Post Earnings of -$0.23 Per Share|
www.americanbankingnews.com - September 2 at 12:10 PM
|Ocera Therapeutics, Inc. (OCRX) Given Average Recommendation of "Buy" by Brokerages|
www.americanbankingnews.com - August 30 at 10:56 AM
|Ocera Therapeutics Selected to Present an Oral Presentation and Three Posters on OCR-002 at the AASLD Liver ... - Nasdaq|
www.nasdaq.com - August 23 at 9:38 AM
|Ocera Therapeutics Selected to Present an Oral Presentation and Three Posters on OCR-002 at the AASLD Liver Meeting® 2017|
finance.yahoo.com - August 23 at 9:38 AM
|Transition Therapeutics (TTHI) versus Ocera Therapeutics (OCRX) Financial Contrast|
www.americanbankingnews.com - August 19 at 2:26 AM
|Ocera Therapeutics: When A Drug Fails, But Actually Works - Seeking Alpha|
seekingalpha.com - August 10 at 6:26 AM
|Ocera Therapeutics Inc (NASDAQ:OCRX) Receives Average Recommendation of "Buy" from Brokerages|
www.americanbankingnews.com - August 5 at 10:24 AM
|Ocera Therapeutics, Inc. (NASDAQ:OCRX) Issues Quarterly Earnings Results, Beats Estimates By $0.01 EPS|
www.americanbankingnews.com - August 2 at 6:00 PM
|Ocera Therapeutics Reports Second Quarter 2017 Financial Results|
finance.yahoo.com - August 2 at 6:32 AM
|Financial Survey: Ocera Therapeutics (NASDAQ:OCRX) versus Strongbridge Biopharma PLC (SBBP)|
www.americanbankingnews.com - July 27 at 8:11 PM
|Ocera Therapeutics, Inc. (OCRX) Receives Consensus Rating of "Hold" from Brokerages|
www.americanbankingnews.com - July 11 at 10:32 AM
|Ocera Therapeutics (OCRX) Commences Phase 2A Study with Oral OCR-002 in Patients with Cirrhosis - StreetInsider.com|
www.streetinsider.com - June 2 at 9:02 PM
|Ocera Therapeutics (OCRX) Commences Phase 2A Study with Oral OCR-002 in Patients with Cirrhosis|
www.streetinsider.com - June 1 at 7:48 PM
|Ocera Therapeutics to Host KOL Conference Call on Hepatic ... - Nasdaq|
www.nasdaq.com - May 26 at 7:58 PM
Ocera Therapeutics (NASDAQ:OCRX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Ocera Therapeutics (NASDAQ:OCRX) Income Statement, Balance Sheet and Cash Flow Statement
Ocera Therapeutics (NASDAQ OCRX) Stock Chart for Thursday, April, 19, 2018